MajesTEC-3's historic efficacy, Kelonia's clean in vivo data, and Prasad's new superiority requirements create a perfect storm
Should we also be talking about allogeneic CAR-Ts? They are still a viable competitor, especially Allogene which has a 1L high-risk trial ongoing that can solve many of the issues highlighted here.
Should we also be talking about allogeneic CAR-Ts? They are still a viable competitor, especially Allogene which has a 1L high-risk trial ongoing that can solve many of the issues highlighted here.